Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

49.50 +0.31 (+0.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Flowserve Corporation (NYSE – FLS), Streamline Health Solutions, Inc. (Nasdaq – STRM), Sitio Royalties Corp. (NYSE – STR), Vigil Neuroscience, Inc. (Nasdaq – VIGL)
From Brodsky & Smith LLC
Via GlobeNewswire
Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response
Kymera's KT-621 achieved rapid, deep STAT6 degradation and showed a strong safety profile in Phase 1, with the next trials planned through early 2026. 
Via Benzinga
Sanofi To Buy Blueprint Medicines For Up To $9.5B: Retail Sees More Acquisition Offers From European Pharma Companies
Sanofi will pay $129 per share in cash at closing, representing a 27% premium to Blueprint’s closing price on Friday of $101.35. 
Via Stocktwits
Price Over Earnings Overview: Sanofi
Via Benzinga
Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals
Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved efficacy and safety profile. 
Via Benzinga
Exposures COVID-19 Product Safety
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout
Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib. 
Via Benzinga
Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket
Via Benzinga
US Stocks Likely To Open Lower After A Solid May: 'TACO' Trade And 'Run It Hot' Optimism 'Are Consensus At This Point,' Says Expert
U.S. stock futures fell on Monday after a mixed close on Friday. Futures of major benchmark indices were trading lower in premarket. 
Via Benzinga
Campbell's, SAIC And 3 Stocks To Watch Heading Into Monday
Via Benzinga
Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Regeneron Pharmaceuticals Crashes 12% On A Surprise Sanofi-Tied Failure
Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study. 
Via Investor's Business Daily
Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data
Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not meet its main goal. 
Via Benzinga
Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For 'Healthy' Pregnant Women, Children
RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed. 
Via Benzinga
Exposures COVID-19
Sanofi, VNVC Launch Vaccine Manufacturing Facility In Vietnam, Says Report: Retail’s Positive
According to Reuters, operations at the new facility are expected to begin by the end of 2027. 
Via Stocktwits
SANOFI-ADR (NASDAQ:SNY) – A Pharmaceutical Stock With Undervalued Potential
SANOFI-ADR (SNY) offers strong profitability, an attractive dividend, and undervalued metrics, making it a compelling choice for value investors in the pharmaceutical sector. 
Via Chartmill
Analysts Think These Stocks Could More Than Double in Value
Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well. 
Via MarketBeat
Topics World Trade
Exposures Tariff
Navitas (NASDAQ: NVTS) Surges on NVIDIA Deal – SNYR, VIGL, XAGE Lead $2 Stock Watch Now, More Inside
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying
The company is working on an Alzheimer's treatment that increases the activity of TREM2, a neuroinflammation target. 
Via Investor's Business Daily
Vigil Neuroscience Stock Triples Pre-market On Acquisition By Sanofi: Retail Goes Super Bullish
Under the terms of the deal, Sanofi will acquire all outstanding common shares of Vigil for $8 per share in cash at closing. 
Via Stocktwits
Sanofi Boosts Alzheimer's Pipeline With Vigil Neuroscience Acquisition
Sanofi (SNY) to acquire Vigil Neuroscience (VIGL) for $470 million in cash, plus potential $2 per share payout. Acquisition excludes monoclonal antibody program and is expected to be finalized in Q3... 
Via Benzinga
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment
Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall. 
Via Benzinga
Exposures COVID-19 Product Safety
SANOFI-ADR (NASDAQ:SNY) – A Reliable Dividend Stock with Strong Fundamentals
SANOFI-ADR (SNY) offers a strong 4.27% dividend yield with sustainable payouts, solid profitability, and manageable debt, making it a top pick for income investors. 
Via Chartmill
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states. 
Via Benzinga
Bristol-Myers Squibb Strikes $350 Million Deal To End Hawaii's Plavix Lawsuit
Bristol-Myers Squibb will pay $350 million to settle Hawaii's lawsuit over Plavix marketing practices, ending claims without admitting wrongdoing and avoiding trial. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say
JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting... 
Via Stocktwits
Topics ETFs Government Stocks
Exposures Political US Equities
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices. 
Via Investor's Business Daily
Topics Government Stocks
Exposures Political US Equities
COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why
Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year outlook raised above expectations. 
Via Benzinga
Exposures COVID-19
AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma
AstraZeneca's Breztri met primary goals in four asthma trials, including KALOS, LOGOS, LITHOS, and VATHOS, involving over 5,000 patients. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.